Executive leadership at Silo Pharma.
Board of directors at Silo Pharma.
Research analysts covering Silo Pharma.
Recent press releases and 8-K filings for SILO.
Silo Pharma Shareholders Approve Equity Plan Expansion and Reverse Stock Split Authority
SILO
Executive Compensation
Proxy Vote Outcomes
- At its Annual Meeting on October 24, 2025, Silo Pharma, Inc. shareholders approved an amendment to the 2020 Omnibus Equity Incentive Plan, increasing the shares reserved for issuance from 470,000 to 1,400,000.
- The amendment also introduces automatic annual increases to the shares available under the plan, starting January 1, 2026, equal to the lesser of 5% of outstanding common stock or a Board-determined amount.
- Shareholders also granted the Board discretionary authority to implement a reverse stock split at a ratio between 1-for-2 and 1-for-20 before October 24, 2026.
- Additionally, shareholders re-elected Eric Weisblum, Wayne Linsley, Kevin Munoz, and Jeff Pavell to the board of directors and ratified Salberg & Company, P.A. as the independent registered public accounting firm for fiscal year 2025.
Oct 24, 2025, 8:39 PM
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering
SILO
- Silo Pharma, Inc. announced the closing of a registered direct offering of 2,857,143 shares of common stock at a purchase price of $0.875 per share.
- The offering generated approximately $2.5 million in gross proceeds for the company.
- Concurrently, the company issued unregistered warrants to purchase up to 2,857,143 shares of common stock at an exercise price of $0.75 per share, which are immediately exercisable and expire five years from the effective date of a registration statement for resale.
- The net proceeds from the offering are intended for working capital and general corporate purposes.
- H.C. Wainwright & Co. acted as the exclusive placement agent, receiving a 7.5% cash fee and a 1.0% management fee of the gross proceeds, and warrants to purchase up to 214,285 shares at an exercise price of $1.0938 per share.
Oct 1, 2025, 8:30 PM
Silo Pharma Secures Australian Patent for PTSD Drug Candidate
SILO
New Projects/Investments
- Silo Pharma, Inc. announced on September 3, 2025, that IP Australia (the Australian Patent Office) has granted patent number 2020271839 to its research and licensing partner Columbia University for an invention exclusively licensed to Silo.
- This patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD).
- According to Silo CEO Eric Weisblum, this patent strengthens the company's global intellectual property portfolio for SPC-15 and supports plans for its clinical trial development as an innovative therapeutic for PTSD.
- SPC-15 is a serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders and has potential eligibility for the FDA’s streamlined 505(b)(2) regulatory pathway.
Sep 3, 2025, 12:26 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more